| Name | Title | Contact Details |
|---|---|---|
Spencer Clark |
SVP and General Counsel | Profile |
Roxanne Womack |
SVP, Chief Compliance Officer | Profile |
Spencer Clark |
VP and Senior Legal Counsel | Profile |
Kelly Whelan |
VP and Senior Legal Counsel, American and Eastern Groups | Profile |
Synectic is a Milford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MicroMed Laboratories is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tenex Health, Inc. (www.tenexhealth.com) (www.tenexhealthpatient.com) develops and markets innovative therapies for the treatment of tendon pain due to trauma or repetitive motion injuries. The minimally invasive technique utilizes the company's proprietary TX MicroTip™ handpiece to cut and debride diseased tissue in an outpatient setting in under 20 minutes, using only a local anesthetic. Since the surrounding healthy tendon tissue is not disturbed, patients enjoy less discomfort and faster recovery times versus traditional open surgical procedures.
Your partner in Care is a Wakefield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.